

## Regulatory & Reimbursement Task Force

### Ongoing Objectives

1. Our facilities will be measured for more common measures like hospital acquired infections and pneumonia, costs of chemotherapy hospitalizations. We are working to better understand the hospital coding needs that best capture the high acuity of a HCT patient so our hospitals are not at a disadvantage in such reporting.
2. We are working to expand Medicare coverage for allogeneic transplant coverage for myelofibrosis, myeloma and sickle cell anemia and planting seeds for lymphoma coverage.
3. We continue to try to find ways to help seek payment to cover full costs of allogeneic search and procurement.
4. We are partnering with American College of Physicians to work on chronic care management payment and for specialty specific medical home models. HCT care delivery with our institutional pathways, our CIBMTR registry for outcomes measures, and FACT and AABB accreditation agencies is a model for this.
5. We continue to have a strong presence on CPT Editorial Board and RVU Update Committee meetings. Coding changes are being considered there for outpatient chemotherapy and bone marrow aspirations. We will be present to make the needs of our patients and providers are well represented.
6. We are collaborating with UHC for its hospital measures and rvu measure to improve accuracy and validity of data sent to centers.